[Combination of antimetabolites and alkylating agents in the treatment of advanced breast cancer].

Abstract

An association of 5-fluoruracyl (or methotrexate) and cyclophosphamide was used in the treatment of 20 cases of hormone-resistant breast cancer. Five objective regressions were obtained. Mean survival here was 28.25 (S.D. 2.87) months, as opposed to 12.75 (S.D. 6.93) months in the remainder. Side-effects of various kinds were noted in 9 patients.

• Authors: R Germiniani, G Pipino, F Lavorato, S Bressani Doldi
• Journal: Minerva medica (Minerva Med) Vol. 68 Issue 13 Pg. 831-4 (Mar 17 1977) ISSN: 0026-4806 [Print] Italy
• Vernacular Title: L'associazione di antimetaboliti ed alchilanti nel trattamento del cancro mammario in fase avanzata
• PMID: 321989 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Alkylating Agents
• Antimetabolites
• Cyclophosphamide
• Fluorouracil

Topics

• Adult
• Aged
• Alkylating Agents (therapeutic use)
• Antimetabolites (therapeutic use)
• Breast Neoplasms (drug therapy)
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage, therapeutic use)
• Drug Therapy, Combination
• Female
• Fluorouracil (administration & dosage, therapeutic use)
• Humans
• Middle Aged
• Time Factors